Equities Analysts Offer Predictions for Blueprint Medicines Co.’s Q2 2026 Earnings (NASDAQ:BPMC)

Blueprint Medicines Co. (NASDAQ:BPMC) – Analysts at Zacks Research upped their Q2 2026 EPS estimates for Blueprint Medicines in a research note issued on Wednesday, October 9th. Zacks Research analyst A. Chakraborty now anticipates that the biotechnology company will post earnings per share of $0.34 for the quarter, up from their prior forecast of $0.33. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.99) per share.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. The company had revenue of $138.20 million for the quarter, compared to analysts’ expectations of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The business’s revenue for the quarter was up 139.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.19) earnings per share.

Other equities research analysts have also recently issued research reports about the company. Barclays lifted their price target on Blueprint Medicines from $75.00 to $105.00 and gave the company an “equal weight” rating in a report on Monday, July 29th. Morgan Stanley raised their price objective on shares of Blueprint Medicines from $110.00 to $115.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Needham & Company LLC reiterated a “buy” rating and set a $130.00 price objective on shares of Blueprint Medicines in a research note on Thursday, August 1st. Oppenheimer raised their price objective on shares of Blueprint Medicines from $114.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, July 8th. Finally, Robert W. Baird raised their price objective on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

Blueprint Medicines Stock Performance

BPMC opened at $88.81 on Friday. The business’s 50 day moving average is $90.94 and its 200-day moving average is $98.95. The stock has a market cap of $5.63 billion, a PE ratio of -25.97 and a beta of 0.58. The company has a current ratio of 3.71, a quick ratio of 3.65 and a debt-to-equity ratio of 1.06. Blueprint Medicines has a twelve month low of $43.89 and a twelve month high of $121.90.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the sale, the insider now owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of Blueprint Medicines stock in a transaction on Monday, August 5th. The shares were sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now owns 34,729 shares of the company’s stock, valued at $3,236,395.51. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now directly owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently modified their holdings of BPMC. Vanguard Group Inc. lifted its stake in shares of Blueprint Medicines by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock valued at $564,045,000 after purchasing an additional 147,827 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Blueprint Medicines in the 4th quarter valued at $9,768,000. Diversified Trust Co lifted its stake in shares of Blueprint Medicines by 3.6% in the 1st quarter. Diversified Trust Co now owns 14,472 shares of the biotechnology company’s stock valued at $1,373,000 after purchasing an additional 498 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Blueprint Medicines in the 1st quarter valued at $218,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Blueprint Medicines by 67.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,777 shares of the biotechnology company’s stock valued at $1,117,000 after purchasing an additional 4,745 shares during the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.